|
1
|
Ferris SP, Hofmann JW, Solomon DA and
Perry A: Characterization of gliomas: From morphology to molecules.
Virchows Arch. 471:257–269. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Purkait S, Mahajan S, Sharma MC, Sarkar C
and Suri V: Pediatric-type diffuse low grade gliomas:
Histomolecular profile and practical approach to their integrated
diagnosis according to the WHO CNS5 classification. Indian J Pathol
Microbiol. 65 (Suppl):S42–S49. 2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Patel T, Singh G and Goswami P: Recent
updates in pediatric diffuse glioma classification: Insights and
conclusions from the WHO 5th edition. J Med Life. 17:665–670.
2024.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Lassaletta A, Zapotocky M, Bouffet E,
Hawkins C and Tabori U: An integrative molecular and genomic
analysis of pediatric hemispheric low-grade gliomas: An update.
Childs Nerv Syst. 32:1789–1797. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ellison DW, Hawkins C, Jones DTW,
Onar-Thomas A, Pfister SM, Reifenberger G and Louis DN: cIMPACT-NOW
update 4: Diffuse gliomas characterized by MYB, MYBL1, or FGFR1
alterations or BRAFV600E mutation. Acta Neuropathol.
137:683–687. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Suh YY, Lee K, Shim YM, Phi JH, Park CK,
Kim SK, Choi SH, Yun H and Park SH: MYB/MYBL1::QKI fusion-positive
diffuse glioma. J Neuropathol Exp Neurol. 82:250–260.
2023.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Teasdale G and Jennett B: Assessment of
coma and impaired consciousness. A practical scale. Lancet.
2:81–84. 1974.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Wirsching HG, Galanis E and Weller M:
Glioblastoma. Handb Clin Neurol. 134:381–397. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Hu Y, Zhang S, Ye H, Wang G, Chen X and
Zhang Y: Lateral ventricle chordoid meningioma presenting with
inflammatory syndrome in an adult male: A case report. Exp Ther
Med. 25(236)2023.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Pallud J and McKhann GM: Diffuse low-grade
glioma-related epilepsy. Neurosurg Clin N Am. 30:43–54.
2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
PDQ Pediatric Treatment Editorial Board.
Childhood astrocytomas, other gliomas, and glioneuronal/neuronal
tumors treatment (PDQ®): Health professional version.
In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD):
National Cancer Institute (US), 2002.
|
|
13
|
Lombardi D, Marsh R and de Tribolet N: Low
grade glioma in intractable epilepsy: Lesionectomy versus epilepsy
surgery. Acta Neurochir Suppl. 68:70–74. 1997.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hughlings-Jackson J: Observations on the
physiology and pathology of hemi-chorea. Edinb Med J. 14:294–303.
1869.PubMed/NCBI
|
|
15
|
Luyken C, Blümcke I, Fimmers R, Urbach H,
Elger CE, Wiestler OD and Schramm J: The spectrum of long-term
epilepsy-associated tumors: Long-term seizure and tumor outcome and
neurosurgical aspects. Epilepsia. 44:822–830. 2003.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Thom M, Blümcke I and Aronica E: Long-term
epilepsy-associated tumors. Brain Pathol. 22:350–379.
2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Baticulon RE, Wittayanakorn N and Maixner
W: Low-grade glioma of the temporal lobe and tumor-related epilepsy
in children. Childs Nerv Syst. 40:3085–3098. 2024.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Giulioni M, Marucci G, Cossu M, Tassi L,
Bramerio M, Barba C, Buccoliero AM, Vornetti G, Zenesini C,
Consales A, et al: CD34 expression in low-grade epilepsy-associated
tumors: Relationships with clinicopathologic features. World
Neurosurg. 121:e761–e768. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Huse JT, Snuderl M, Jones DTW, Brathwaite
CD, Altman N, Lavi E, Saffery R, Sexton-Oates A, Blumcke I, Capper
D, et al: Polymorphous low-grade neuroepithelial tumor of the young
(PLNTY): An epileptogenic neoplasm with oligodendroglioma-like
components, aberrant CD34 expression, and genetic alterations
involving the MAP kinase pathway. Acta Neuropathol. 133:417–429.
2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Schindler G, Capper D, Meyer J, Janzarik
W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C,
Hasselblatt M, et al: Analysis of BRAF V600E mutation in 1,320
nervous system tumors reveals high mutation frequencies in
pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar
pilocytic astrocytoma. Acta Neuropathol. 121:397–405.
2011.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Vuong HG, Altibi AMA, Duong UNP, Ngo HTT,
Pham TQ, Fung KM and Hassell L: BRAF mutation is associated with an
improved survival in glioma-a systematic review and meta-analysis.
Mol Neurobiol. 55:3718–3724. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Louis DN, Perry A, Wesseling P, Brat DJ,
Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM,
Reifenberger G, et al: The 2021 WHO classification of tumors of the
central nervous system: A summary. Neuro Oncol. 23:1231–1251.
2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Orhan O, Eray HA, Alpergin BC, Zaimoglu M,
Ozpiskin OM, Aras N, Heper A and Eroglu U: Polymorphous low-grade
neuroepithelial tumor of the young (PLNTY): A case report with
surgical and neuropathological differential diagnosis. Clin
Neuropathol. 43:83–91. 2024.PubMed/NCBI View
Article : Google Scholar
|
|
24
|
Surrey LF, Jain P, Zhang B, Straka J, Zhao
X, Harding BN, Resnick AC, Storm PB, Buccoliero AM, Genitori L, et
al: Genomic analysis of dysembryoplastic neuroepithelial tumor
spectrum reveals a diversity of molecular alterations dysregulating
the MAPK and PI3K/mTOR pathways. J Neuropathol Exp Neurol.
78:1100–1111. 2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ryall S, Zapotocky M, Fukuoka K, Nobre L,
Guerreiro Stucklin A, Bennett J, Siddaway R, Li C, Pajovic S,
Arnoldo A, et al: Integrated molecular and clinical analysis of
1,000 pediatric low-grade gliomas. Cancer Cell. 37:569–583.e5.
2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Yang RR, Aibaidula A, Wang WW, Chan AK,
Shi ZF, Zhang ZY, Chan DTM, Poon WS, Liu XZ, Li WC, et al:
Pediatric low-grade gliomas can be molecularly stratified for risk.
Acta Neuropathol. 136:641–655. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zhang J, Wu G, Miller CP, Tatevossian RG,
Dalton JD, Tang B, Orisme W, Punchihewa C, Parker M, Qaddoumi I, et
al: Whole-genome sequencing identifies genetic alterations in
pediatric low-grade gliomas. Nat Genet. 45:602–612. 2013.PubMed/NCBI View
Article : Google Scholar
|
|
28
|
Jones DTW, Hutter B, Jäger N, Korshunov A,
Kool M, Warnatz HJ, Zichner T, Lambert SR, Ryzhova M, Quang DA, et
al: Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic
astrocytoma. Nat Genet. 45:927–932. 2013.PubMed/NCBI View
Article : Google Scholar
|
|
29
|
Bandopadhayay P, Ramkissoon LA, Jain P,
Bergthold G, Wala J, Zeid R, Schumacher SE, Urbanski L, O'Rourke R,
Gibson WJ, et al: MYB-QKI rearrangements in angiocentric glioma
drive tumorigenicity through a tripartite mechanism. Nat Genet.
48:273–282. 2016.PubMed/NCBI View
Article : Google Scholar
|
|
30
|
Manoharan N, Liu KX, Mueller S, Haas-Kogan
DA and Bandopadhayay P: Pediatric low-grade glioma: Targeted
therapeutics and clinical trials in the molecular era. Neoplasia.
36(100857)2023.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Rivera B, Gayden T, Carrot-Zhang J, Nadaf
J, Boshari T, Faury D, Zeinieh M, Blanc R, Burk DL, Fahiminiya S,
et al: Germline and somatic FGFR1 abnormalities in dysembryoplastic
neuroepithelial tumors. Acta Neuropathol. 131:847–863.
2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Qaddoumi I, Orisme W, Wen J, Santiago T,
Gupta K, Dalton JD, Tang B, Haupfear K, Punchihewa C, Easton J, et
al: Genetic alterations in uncommon low-grade neuroepithelial
tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and
align with morphology. Acta Neuropathol. 131:833–845.
2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Yeo KK, Alexandrescu S, Cotter JA,
Vogelzang J, Bhave V, Li MM, Ji J, Benhamida JK, Rosenblum MK, Bale
TA, et al: Multi-institutional study of the frequency, genomic
landscape, and outcome of IDH-mutant glioma in pediatrics. Neuro
Oncol. 25:199–210. 2023.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Bale TA and Rosenblum MK: The 2021 WHO
classification of tumors of the central nervous system: An update
on pediatric low-grade gliomas and glioneuronal tumors. Brain
Pathol. 32(e13060)2022.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Kakadia S, Yarlagadda N, Awad R, Kundranda
M, Niu J, Naraev B, Mina L, Dragovich T, Gimbel M and Mahmoud F:
Mechanisms of resistance to BRAF and MEK inhibitors and clinical
update of US food and drug administration-approved targeted therapy
in advanced melanoma. Onco Targets Ther. 11:7095–7107.
2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Nicolaides T, Nazemi KJ, Crawford J,
Kilburn L, Minturn J, Gajjar A, Gauvain K, Leary S, Dhall G, Aboian
M, et al: Phase I study of vemurafenib in children with recurrent
or progressive BRAFV600E mutant brain tumors: Pacific
pediatric neuro-oncology consortium study (PNOC-002). Oncotarget.
11:1942–1952. 2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Ullrich NJ, Prabhu SP, Reddy AT, Fisher
MJ, Packer R, Goldman S, Robison NJ, Gutmann DH, Viskochil DH,
Allen JC, et al: A phase II study of continuous oral mTOR inhibitor
everolimus for recurrent, radiographic-progressive
neurofibromatosis type 1-associated pediatric low-grade glioma: A
neurofibromatosis clinical trials consortium study. Neuro Oncol.
22:1527–1535. 2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
de Visser KE and Joyce JA: The evolving
tumor microenvironment: From cancer initiation to metastatic
outgrowth. Cancer Cell. 41:374–403. 2023.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Bejarano L, Jordāo MJC and Joyce JA:
Therapeutic targeting of the tumor microenvironment. Cancer Discov.
11:933–959. 2021.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Rajendran S, Hu Y, Canella A, Peterson C,
Gross A, Cam M, Nazzaro M, Haffey A, Serin-Harmanci A, Distefano R,
et al: Single-cell RNA sequencing reveals immunosuppressive myeloid
cell diversity during malignant progression in a murine model of
glioma. Cell Rep. 42(112197)2023.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Jones DTW, Kocialkowski S, Liu L, Pearson
DM, Bäcklund LM, Ichimura K and Collins VP: Tandem duplication
producing a novel oncogenic BRAF fusion gene defines the majority
of pilocytic astrocytomas. Cancer Res. 68:8673–8677.
2008.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Sievert AJ, Lang SS, Boucher KL, Madsen
PJ, Slaunwhite E, Choudhari N, Kellet M, Storm PB and Resnick AC:
Paradoxical activation and RAF inhibitor resistance of BRAF protein
kinase fusions characterizing pediatric astrocytomas. Proc Natl
Acad Sci USA. 110:5957–5962. 2013.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Wang H, Long-Boyle J, Winger BA,
Nicolaides T, Mueller S, Prados M and Ivaturi V: Population
pharmacokinetics of vemurafenib in children with
recurrent/refractory BRAF gene V600E-mutant astrocytomas. J Clin
Pharmacol. 60:1209–1219. 2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Wen PY, Stein A, van den Bent M, De Greve
J, Wick A, de Vos FYFL, von Bubnoff N, van Linde ME, Lai A, Prager
GW, et al: Dabrafenib plus trametinib in patients with
BRAFV600E-mutant low-grade and high-grade glioma (ROAR):
A multicentre, open-label, single-arm, phase 2, basket trial.
Lancet Oncol. 23:53–64. 2022.PubMed/NCBI View Article : Google Scholar
|
